Ash RA, Harvey AM and Tasker S (2005) Primary hyperaldosteronism in the cat: a series of 13 cases. Journal of Feline Medicine and Surgery 7, 173–182

Bernay F, Bland JM, Haggstrom J et al. (2010) Efficacy of spironolactone on survival in dogs with naturally occurring mitral regurgitation caused by myxomatous mitral valve disease. Journal of Veterinary Internal Medicine 24, 331–341

James RA, Guillot E, Gilmour J et al. (2015) Efficacy of spironolactone (SP) following oral administration of SP in cats with heart failure: final results of the SEISICAT study. Proceedings of the 25th ECVIM-CA Congress, Lisbon

Jeunesse E, Woehrle F, Schneider M and Lefebvre HP (2007) Effect of spironolactone on diuresis and urine sodium and potassium excretion in healthy dogs. Journal of Veterinary Cardiology 9, 63–68

Keene BW, Atkins CE, Bonagura JD et al. (2019) ACVIM consensus guidelines for the diagnosis and treatment of myxomatous mitral valve disease in dogs. Journal of Veterinary Internal Medicine 33, 1127–1140

Lefebvre HP, Ollivier E, Atkins CE et al. (2013) Safety of spironolactone in dogs with chronic heart failure because of degenerative valvular disease: a population-based, longitudinal study. Journal of Veterinary Internal Medicine 27, 1083–1091

Pitt B (2004) Effect of aldosterone blockade in patients with systolic left ventricular dysfunction: implications of the RALES and EPHESUS studies. Molecular and Cellular Endocrinology 217, 53–58